Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

http://www.wikidata.org/entity/Q37835612

about

Incretin therapy--present and future.Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.The cardiovascular safety of incretin-based therapies: a review of the evidence.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

P2860

Q35760283-B7237349-D363-44F9-9463-DE006E29A6B8 Q36016914-0C99C3DC-9DA6-4EE7-80BE-95B55FE56C60 Q36941700-D0D7953A-41F8-4890-BABA-C77E4C9E5814 Q37890793-BA185BC2-7221-4ADB-B9F6-B1B960A219A4 Q38134902-FF2B2AD9-5168-4825-A269-7135CC76374C Q38841043-44B40F97-61DB-47C5-8F5B-4655FA95BC15 Q51322701-6E90FEC7-51D6-4CF5-BC25-C1C44D694799

P2860

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

http://www.wikidata.org/entity/Q37835612

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@en

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@nl

type

label

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@en

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@nl

prefLabel

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@en

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@nl

P1433

Q37835612-81AE8AA9-5D1F-462B-B624-E2CEDBCD7BF0

P1476

Q37835612-0398CEEB-B728-411C-BC4F-D96CE296C288

P2093

Q37835612-435A8E0D-2FE3-40CA-8E04-3E30EF8023BE

P2860

Q37835612-010404D1-DE3E-415E-96C1-1F85E23149B6

Q37835612-11E8ECA0-EE54-425F-A749-EB67027787B1

Q37835612-19232F84-FA31-42AD-8412-2001D883D78B

Q37835612-1F12777E-4CC6-43CF-BD59-D9D2D86CFA55

Q37835612-229367B6-7B89-4EEC-925D-DB2B3FD77766

Q37835612-26723B87-1251-478C-B6B1-4FF9E80CCAA3

Q37835612-2A8746C1-4FA9-4CBF-9C4F-6A07BA511545

Q37835612-2E0E324C-9F4F-47DB-ABA4-C04F854E8583

Q37835612-2F11CCF0-18E1-463E-BE26-A86C3387F9BD

Q37835612-2F1CA38D-CFC8-48A9-83DF-A1AEF271C32D

P304

Q37835612-7729D748-9A3D-430B-96EA-46FE133645DC

P31

Q37835612-E6815639-4674-412F-BEF1-C1CE81D2BCDF

P356

Q37835612-6EE49EAD-B940-4611-BE46-24358DDA41E3

P407

Q37835612-3E50C8B2-9DDD-4E73-A4D0-3A54401DB6FE

P433

Q37835612-02CB1162-0E66-4C70-A983-607EDFC80527

P478

Q37835612-65AF8AFA-C70D-4D5F-9792-D65AA3475C24

P577

Q37835612-ADBB1910-4BB2-47C1-8386-725940F1B6A0

P698

Q37835612-C67AE416-C627-4BBB-9C32-7A27B7EAF913

P921

Q37835612-5DB7BFDF-18BC-4EE2-A4ED-FEB7B26381C2

P356

PGM.2011.01.2245

P1433

Postgraduate Medicine

P1476

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

@en

P2093

Paul S Jellinger

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

DPP-4 inhibitors.

P304

53-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2011.01.2245

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21293084

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes